Evidence map›Paper›PMID 31890882›Full record

ArticleLaryngoscope investigative otolaryngology2019

Implementing Efficient Peptoid-Mediated Delivery of RNA-Based Therapeutics to the Vocal Folds.

Shigeyuki Mukudai, Iv Kraja, Renjie Bing, Danielle M Nalband, Mallika Tatikola, Nao Hiwatashi, Kent Kirshenbaum, Ryan C Branski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Preclinical Vocal Fold and Airway Injury Models: A Scoping Review.Laryngoscope investigative otolaryngology · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shigeyuki MukudaiNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery New York University School of Medicine, New York New York U.S.A.
Iv KrajaNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery New York University School of Medicine, New York New York U.S.A.
Renjie BingNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery New York University School of Medicine, New York New York U.S.A.
Danielle M NalbandDepartment of Chemistry New York University, New York New York U.S.A.
Mallika TatikolaDepartment of Chemistry New York University, New York New York U.S.A.
Nao HiwatashiNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery New York University School of Medicine, New York New York U.S.A.
Kent KirshenbaumDepartment of Chemistry New York University, New York New York U.S.A.
Ryan C BranskiNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery New York University School of Medicine, New York New York U.S.A.ORCID https://orcid.org/0000-0003-1190-9036
New York University · US

Funding

Optimal RNA-based therapeutics for vocal fold injury and fibrosisR01DC013277 · NIDCD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BRANSKI, RYAN COMFORT · 2014 to 2018
$2.3M
NIDCD NIH HHS R01 DC013277
6 · The paper itself

Abstract

objectiveWe hypothesize that Smad3 is a master regulator of fibrosis in the vocal folds (VFs) and RNA-based therapeutics targeting Smad3 hold therapeutic promise. Delivery remains challenging. We previously described a novel synthetic peptoid oligomer, lipitoid

methodsIn vitro, Smad3 knockdown by various lipitoid variants was evaluated via quantitative real-time polymerase chain reaction in human VF fibroblasts. Cytotoxicity was quantified via colorimetric assays. In vivo, a rabbit model of VF injury was employed to evaluate the temporal dynamics of Smad3 knockdown following injection of the

resultsIn vitro, similar reductions in Smad3 expression were established by all lipitoid variants, with one exception. Sequence variants also exhibited similar nontoxic characteristics; no statistically significant differences in cell proliferation were observed. In vivo, Smad3 expression was significantly reduced in injured VFs following injection of

conclusionsIn spite of the chemical diversity of these peptoid transfection reagents, the sequence variants generally provided consistently efficient reductions in Smad3 expression. LEVEL OF EVIDENCE: NA.

Indexed as

fibrosislipitoidsiRNASmad3vocal foldVoice

Identifiers

PMID31890882
PMCPMC6929602
OpenAlexW2981997748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.